Medicare Coverage Of PET Pharmaceutical Agents Needs Revamp, Industry Says
This article was originally published in The Gray Sheet
Executive Summary
A broad range of stakeholders are asking CMS to remove national non-coverage language for newly approved radiopharmaceuticals used in positron emission tomography to allow speedier access to new tools for diagnosing Alzheimer’s and other diseases.